Savvy Update, 3/27/23: Non-Invasive Monitoring: Know Labs & Hagar’s GWave, California’s Brand of Insulin, Steatosis in Adult T1Ds, MDs Leaving Their Jobs, Colorectal Cancers in Adult T1Ds, Off-Label Prescribing

Savvy Update, 3/27/23: Non-Invasive Monitoring: Know Labs & Hagar’s GWave, California’s Brand of Insulin, Steatosis in Adult T1Ds, MDs Leaving Their Jobs, Colorectal Cancers in Adult T1Ds, Off-Label Prescribing

Mar 27, 2023 | Featured, Research News, Technology Updates

Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring by Sean Whooley for DrugDeliveryBusiness.com, 22 March 2023. Know Labs announced that it established a scientific advisory board to accelerate the development of its glucose...
Savvy Updates, 3/20/23: Vertex Cleared for VX-264 Trials, Nemaura Medical & SugarBeat, Insulin Leads to Smaller Pancreas, Insulet Joins S&P500, Insulin Costs & Price Cuts, Sanofi Buys ProventionBio

Savvy Updates, 3/20/23: Vertex Cleared for VX-264 Trials, Nemaura Medical & SugarBeat, Insulin Leads to Smaller Pancreas, Insulet Joins S&P500, Insulin Costs & Price Cuts, Sanofi Buys ProventionBio

Mar 20, 2023 | Featured, Research News, Technology Updates

New Vertex Type 1 Stem Cell Therapy Gets FDA Nod to Enter Clinical Trials by Andrew Briskin for diaTribe.org, 9 March 2023.   The FDA announced that a new type 1 diabetes stem cell therapy from Vertex has been cleared to enter clinical trials in the United...
Skip to content